Priorities and Standards in Pharmacogenomic Research Opportunities for a Safer...
Priorities and Standards in Pharmacogenomic Research Opportunities for a Safer and More Efficient Pharmacotherapy
Pharmacogenomics is the scientific discipline that relates inter-individual variation in drug response to genetic variation. While there have been major advances in basic genomic knowledge and genotyping technologies, translation...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PharmGenHUB
Pharmacogenomics Hub in a strengthened IMGGE
1M€
Cerrado
PharmGenHUB
Pharmacogenomics Hub in a strengthened IMGGE
1M€
Cerrado
PREDICTION-ADR
Personalisation of tREatment In Cardiovascular disease throu...
4M€
Cerrado
SAF2012-35779
IDENTIFICACION DE MARCADORES PREDICTIVOS DE LA NEUROTOXICIDA...
117K€
Cerrado
U-PGx
Ubiquitous Pharmacogenomics U PGx Making actionable pharm...
15M€
Cerrado
PDC2021-121243-I00
PLATAFORMA DELFOS: SISTEMA DE INFORMACION PARA LA GESTION DE...
102K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Pharmacogenomics is the scientific discipline that relates inter-individual variation in drug response to genetic variation. While there have been major advances in basic genomic knowledge and genotyping technologies, translation into clinical practice has been slow. It is essential we quicken the pace of translational research in pharmacogenomics - at present, we cannot define which patients are going to respond to drugs, and which patients are going to develop adverse drug reactions. In this ITN, our concerted action across the EU, in cooperation with US researchers will train young investigators and clinicians (14 ESR and 2 ER) to establish, evaluate and retrieve relevant genetic information from patients, and relate it to clinical outcomes of drug therapy. This will be achieved through sharing patient materials, performing pooled analyses, transfer of knowledge and skills across laboratories and provide access to high-throughput technology platforms between 5 academic (3 EU, 1 ICPC, 1 OTC partners) and 4 industry partners (3 EU, 1AC partner). This will enhance translational research, promote uniform drug treatment standards throughout Europe and worldwide, and improve the competitiveness of the EU in this emerging and exciting field.